iBio, Inc.

iBio, Inc. develops pharmaceutical product applications using its iBio Technology platform; a platform that has proven to be more efficient and cost-effective than traditional systems. The iBioLaunch platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins, and vaccines.

Services Provided:

  • We applied strategic marketing techniques toward enhancing interest in the institutional and analysts community.
  • Identified key financial media contacts to best convey and clarify the company’s message.
  • Created articles and feature materials for industry publications and distribution throughout our investor network, including blogs and investment newsletters.
  • Analyzed and researched peer competitors in the sector to better attract and differentiate our clients’ value proposition to active and targeted investors.


  • Increased the 20d average volume from 50K shares a day to over 120K.
  • Coverage increased with two new analyst buy recommendations.
  • Within 60 days the stock price increased from $0.77 to $1.95 on record volume for the company’s shares.
  • 2.5X increase in market capitalization,  unlocking value for existing shareholders and lowering the cost of capital for the client.
  • Subsequently allowing the company to execute an equity raise for over $10 million.


More Client Stories

CEO, Usio, Inc.

Louis Hoch

CEO, Sonoma Pharmaceuticals

Jim Schutz

Former CEO, IsoRay

Dwight Babcock


We help you market your investment story with maximum impact and deliver your corporate message effectively

Contact Us
or call
+1 954 360 9998